ClinicalTrials.gg
CompletedNCT02994446SERF-VTUpdated Apr 28, 2022

Saline-Enhanced Radiofrequency (SERF) Catheter Ablation for the Treatment of Ventricular Tachycardia

An interventional study of Saline-Enhanced Radiofrequency Catheter and Ablation System in Tachycardia, Ventricular, sponsored by Thermedical, Inc.. Completed at 3 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-04-28.

Sponsored by Thermedical, Inc. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 54 studies in Tachycardia, Ventricular with a site in Canada — 17 open to participants now, 19 under way, 2 of them phase 3. Tachycardia, Ventricular · Canada.

Enrollment
27th of 39
25 · median 130
Started
2016
with 2 others
No phase
19 of 54
8 open now
Registered
20th of 54
by date

Among the 54 studies in Tachycardia, Ventricular with a site in Canada, this one is the 27th largest by enrollment of the 39 interventional ones that give a count, is one of 3 that started in 2016, is one of 19 with no phase, and was the 20th registered.

Tachycardia, Ventricular

452 studies on the registry are indexed under Tachycardia, Ventricular; 121 are open to participants now.

Browse Tachycardia, Ventricular studies →

Open to participants now

17 of the 54 studies in Tachycardia, Ventricular with a site in Canada are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 86 Tachycardia, Ventricular studies recruiting now, 67 (78%) set no upper age limit and 1 (1%) stops at 75 or younger; 7 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Tachycardia, Ventricular with a site in Canada, or all of them as a file.
02

Study summary

The purpose of this study is to demonstrate the technical feasibility of the SERF Catheter and SERF Cardiac Ablation System to eliminate or control ventricular tachycardia (VT)

03

Conditions studied

  • Tachycardia, Ventricular
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient has recurrent, symptomatic, monomorphic VT
  2. Patient has drug or drug intolerant VT following use of at least one Class III antiarrhythmic as demonstrated by a recurrent arrhythmia and is not a suitable candidate per the investigator's expert opinion for ongoing or alternative drug therapy
  3. A prior failed ablation as evidenced by ICD device therapy within the prior 6 months.
  4. Patient has minimum 3 month ICD interrogation history available for evaluation
  5. Patient has > 20%, confirmed by echo or comparable technique during baseline evaluation
  6. Patient is at least 18 years old
  7. Patient has signed the , and is willing and able to participate in all study procedures and follow up requirements

Exclusion criteria

Exclusion Criteria

  1. Patients with idiopathic VT
  2. Patients with VT with or MRI/CT findings suggestive of right ventricular free wall origin findings.
  3. Patients with VTs of septal origin may be excluded as such ablations require special care to minimize the risk of heart block, particularly within 2 cm of the AV node/proximal conduction system. Patients requiring ablation at such locations should only be included when the arrhythmia itself is life-threatening or otherwise sufficiently severe to justify the risk.
  4. Patient with myocardial infarction (MI) or unstable angina within previous 60 days
  5. Patient with cardiac surgery or percutaneous coronary intervention (PCI) within previous 60 days
  6. Patient with class IV () heart failure
  7. Patient with mechanical mitral valve, severe aortic stenosis or flail mitral leaflet
  8. Patient with left ventricular assist device planned or required for the procedure
  9. Patients with co-morbidities such that they have less than 1 year
  10. Patient with significant intracardiac and/or laminated thrombus evident by transesophogeal echo (TEE) or transthoracic echo (TTE) (with contrast) within 2 days of the ablation procedure
  11. Patient with thrombocytopenia or other coagulopathy
  12. Women who are or may potentially be pregnant. (must be or have a negative pregnancy test)
  13. Patient with other acute illness or active systemic infection (unrelated to VT or its origin)
  14. Significant congenital anomaly heart disease or anomaly
  15. Allergy or to the medications/agents used during a standard ablation/EP intervention.
  16. Patient concurrently enrolled in any other drug or device study that the investigator deems would interfere with study results.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    SERF Catheter Ablation

    Ablation of ventricular tachycardia with a saline-enhanced radiofrequency ablation catheter

    Device: Saline-Enhanced Radiofrequency Catheter and Ablation System

Interventions

  • DeviceSaline-Enhanced Radiofrequency Catheter and Ablation System

    Ablation of ventricular tachycardia with a saline-enhanced radiofrequency ablation catheter

    Also known as: SERF Ablation System and Durablate™ Ablation Catheter

06

What researchers measure

Primary outcomes

  1. Serious Adverse Events that are potentially device-related

    Time frame: Within 30 days of ablation

  2. Major Adverse Cardiac Events

    MACE will be accessed from time of ablation to time of discharge from hospital following the ablation (generally within 2 days of ablation procedure).

    Time frame: Within 2 days after ablation procedure

  3. Non-inducibility of clinical ventricular tachycardia (VT) and/or elimination of clinically relevant scar or channels

    Time frame: At completion of ablation procedure

Secondary outcomes

  1. Intraprocedural non-inducibility and/or scar homogenization of target VT

    Time frame: At completion of ablation procedure

  2. Elimination of the target VT and/or reduction in number of VT episodes

    Time frame: Within first 6 months of ablation procedure

07

Study locations

3 sites
  • Southlake Regional Health Centre
    Newmarket, Ontario L3Y-2P6, Canada
  • Montreal Heart Institute - Institut de Cardiologie de Montréal
    Montréal, Quebec H1T 1C8, Canada
  • Quebec Heart and Lung Institute - Institut universitaire de cardiologie et de pneumologie de Québec
    Québec, Canada
08

References and documents

Publications

  • Packer DL, Wilber DJ, Kapa S, Dyrda K, Nault I, Killu AM, Kanagasundram A, Richardson T, Stevenson W, Verma A, Curley M; SERF Investigators. Ablation of Refractory Ventricular Tachycardia Using Intramyocardial Needle Delivered Heated Saline-Enhanced Radiofrequency Energy: A First-in-Man Feasibility Trial. Circ Arrhythm Electrophysiol. 2022 Aug;15(8):e010347. doi: 10.1161/CIRCEP.121.010347. Epub 2022 Jul 1. PubMed 35776711 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2016 to primary completion in Apr 2021, 52 months.

Of 40 industry-sponsored interventional studies with no phase under Tachycardia, Ventricular, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 52. This study's 52 months is above that.

Counting every sponsor, half of 126 studies reached it within 36 months; a quarter within 20 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2016
First posted
Dec 15, 2016
StartActual
Dec 2016
Primary completionActual
Apr 21, 2021
CompletionActual
Oct 4, 2021
Last update
Apr 28, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02994446
Lead sponsor
Thermedical, Inc.
Responsible party
Sponsor
First posted
Dec 15, 2016
Start date
Dec 2016
Primary completion
Apr 21, 2021
Completion
Oct 4, 2021
Last update
Apr 28, 2022

Study contacts

Douglas L. Packer, MD
study director · Mayo Clinic
Atul Verma, MD
principal investigator · Southlake Regional Health Centre

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion